Sooma Medical Receives FDA Breakthrough Device Designation For Its Innovative At-Home Depression Treatment Device

HELSINKI, March 6, 2023 /PRNewswire/ -- Sooma Medical, a medical device company based in Finland, has been granted Breakthrough Device designation by the U.S. Food and Drug Administration (FDA) for its portable, patient-administered neuromodulation device to treat depression.

This revolutionary treatment utilises a mild electrical current to stimulate targeted brain areas, significantly improving depressive symptoms. The FDA's breakthrough designation is reserved for novel therapies that show significant potential to provide a substantial improvement over existing options for severe or life-threatening conditions.

"We are thrilled to receive this breakthrough designation from the FDA," said Tuomas Neuvonen, CEO of Sooma. "This is a huge step forward for our company and, more importantly, for the millions of people suffering from depression. We are committed to making this innovative treatment accessible to patients in the U.S. as quickly as possible."

Depression is a serious mental health condition that affects millions of people worldwide. Current treatment options, such as antidepressants and psychotherapy, can be effective but also have limitations. Sooma Depression Therapy offers a new, non-invasive alternative that has the potential to significantly improve the lives of those suffering from depression.

Sooma Medical is dedicated to developing innovative and accessible solutions to improve the lives of people affected by mental health conditions. The company continues to work closely with the FDA to bring this treatment to the market and to make it available to more patients as soon as possible.

About Sooma Depression Therapy

Sooma Depression Therapy, already approved in the EU, is an effective first-hand treatment option for depression used by hundreds of patients annually in more than 30 countries. The therapy, which is painless and involves no medication, is always prescribed by a medical professional.

The treatment consists of daily 30-minute sessions for a minimum of three weeks. It can also be used as a stand-alone treatment or as an add-on therapy along with other types of treatment, such as pharmaceuticals, without the risk of dangerous drug interactions.

Most patients can feel relief from their depressive symptoms around the third week of treatment. According to Sooma's post-market data, more than half of patients achieve a complete clinical response, meaning a 50% or greater improvement in their depressive symptoms after the treatment.

About Sooma

Sooma Medical is a Finnish medical device company established in 2013, which works closely with leading experts in psychiatry and clinical neurophysiology to develop effective treatment solutions for health conditions in these areas. Sooma medical devices are engineered and manufactured in Finland following the international ISO 13485 quality management system for medical devices. Devices developed by Sooma have received approvals from international health authorities such as Health Canada, MDA, HSA, TGA and COFEPRIS. To date, more than 10,000 patients have found relief with these treatments. Sooma Depression Therapy is available in more than 30 countries worldwide.

For more information, please contact Irene Pérez Molina at irene@soomamedical.com.

View original content:https://www.prnewswire.com/news-releases/sooma-medical-receives-fda-breakthrough-device-designation-for-its-innovative-at-home-depression-treatment-device-301762184.html

SOURCE Sooma Medical

First published on Mon, Mar 6, 2023

Enjoyed what you've read so far? Great news - there's more to explore!

Stay up to date with the latest news, a vast collection of tech articles including introductory guides, product reviews, trends and more, thought-provoking interviews, hottest AI blogs and entertaining tech memes.

Plus, get access to branded insights such as informative white papers, intriguing case studies, in-depth reports, enlightening videos and exciting events and webinars from industry-leading global brands.

Dive into TechDogs' treasure trove today and Know Your World of technology!

Disclaimer - Reference to any specific product, software or entity does not constitute an endorsement or recommendation by TechDogs nor should any data or content published be relied upon. The views expressed by TechDogs' members and guests are their own and their appearance on our site does not imply an endorsement of them or any entity they represent. Views and opinions expressed by TechDogs' Authors are those of the Authors and do not necessarily reflect the view of TechDogs or any of its officials. While we aim to provide valuable and helpful information, some content on TechDogs' site may not have been thoroughly reviewed for every detail or aspect. We encourage users to verify any information independently where necessary.

Tags:

Sooma Medical Medical devices Neuromodulation Neurological devices

Join The Discussion

Arctiq Acquires Shadow-Soft To Expand Observability And Automation Expertise

Compal Introduces High-Density NVIDIA HGX Rubin NVL8 Integrated Solution At GTC 2026

Niche Launches College Financial Aid Comparison Tool To Help Families Decode And Compare Offers

Shoplazza Adopts Agentic Commerce Architecture To Power AI-Driven E-Commerce Operations

Tata Communications Receives Frost & Sullivan's 2025 Global Company Of The Year Recognition For Leadership In Video-Managed Services